Dylan T Wolff1, Thomas F Monaghan2, Danielle J Gordon3,4, Kyle P Michelson5, Tashzna Jones6, Raymond Khargi3,4, Matthew T Smith3,4, Fenizia Maffucci7, Hyezo Kwun8, Nicholas R Suss9, Andrew G Winer3,4. 1. Department of Urology, Wake Forest School of Medicine, Winston-Salem, NC 27101, USA. 2. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 3. Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA. 4. Department of Urology, Kings County Hospital Center, Brooklyn, NY 11203, USA. 5. Department of Urology, University of South Florida, Tampa, FL 33606, USA. 6. Department of Urology, Yale University School of Medicine, New Haven, CT 06520, USA. 7. Department of Urology, Temple University Hospital, Philadelphia, PA 19104, USA. 8. Division of Urology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. 9. Department of Surgery, University of Chicago, Chicago, IL 60637, USA.
Abstract
Background and Objectives: The National Cancer Database (NCDB) captures nearly 70% of all new cancer diagnoses in the United States, but there exists significant variation in this capture rate based on primary tumor location and other patient demographic factors. Prostate cancer has the lowest coverage rate of all major cancers, and other genitourinary malignancies likewise fall below the average NCDB case coverage rate. We aimed to explore NCDB coverage rates for patients with genitourinary cancers as a function of race. Materials and Methods: We compared the incidence of cancer cases in the NCDB with contemporary United States Cancer Statistics data. Results: Across all malignancies, American Indian/Alaskan Natives subjects demonstrated the lowest capture rates, and Asian/Pacific Islander subjects exhibited the second-lowest capture rates. Between White and Black subjects, capture rates were significantly higher for White subjects overall and for prostate cancer and kidney cancer in White males, but significantly higher for bladder cancer in Black versus White females. No significant differences were observed in coverage rates for kidney cancer in females, bladder cancer in males, penile cancer, or testicular cancer in White versus Black patients. Conclusions: Differential access to Commission on Cancer-accredited treatment facilities for racial minorities with genitourinary cancer constitutes a unique avenue for health equity research.
Background and Objectives: The National Cancer Database (NCDB) captures nearly 70% of all new cancer diagnoses in the United States, but there exists significant variation in this capture rate based on primary tumor location and other patient demographic factors. Prostate cancer has the lowest coverage rate of all major cancers, and other genitourinary malignancies likewise fall below the average NCDB case coverage rate. We aimed to explore NCDB coverage rates for patients with genitourinary cancers as a function of race. Materials and Methods: We compared the incidence of cancer cases in the NCDB with contemporary United States Cancer Statistics data. Results: Across all malignancies, American Indian/Alaskan Natives subjects demonstrated the lowest capture rates, and Asian/Pacific Islander subjects exhibited the second-lowest capture rates. Between White and Black subjects, capture rates were significantly higher for White subjects overall and for prostate cancer and kidney cancer in White males, but significantly higher for bladder cancer in Black versus White females. No significant differences were observed in coverage rates for kidney cancer in females, bladder cancer in males, penile cancer, or testicular cancer in White versus Black patients. Conclusions: Differential access to Commission on Cancer-accredited treatment facilities for racial minorities with genitourinary cancer constitutes a unique avenue for health equity research.
Authors: Mary C White; David K Espey; Judith Swan; Charles L Wiggins; Christie Eheman; Judith S Kaur Journal: Am J Public Health Date: 2014-04-22 Impact factor: 9.308
Authors: David K Espey; Charles L Wiggins; Melissa A Jim; Barry A Miller; Christopher J Johnson; Tom M Becker Journal: Cancer Date: 2008-09-01 Impact factor: 6.860
Authors: Jennifer N Sims; Clement G Yedjou; Daniel Abugri; Marinelle Payton; Timothy Turner; Lucio Miele; Paul B Tchounwou Journal: Int J Environ Res Public Health Date: 2018-05-28 Impact factor: 3.390
Authors: Ken Batai; Alfredo Harb-De la Rosa; Jiping Zeng; Juan J Chipollini; Francine C Gachupin; Benjamin R Lee Journal: Cancer Med Date: 2019-09-11 Impact factor: 4.452